Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel plus capecitabine first-line treatment for recurrent or metastatic cholangiocarcinoma
ChiCTR1900025004Phase 2Completed
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Mar 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and capecitabine in cholangiocarcinoma (CCA) and gallbladder cancer, sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Objective response rate. Started Mar 2019; status: completed.
02
Drugs
paclitaxelcapecitabine
03
Conditions
cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR1900025004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025004.